Skip to main content

Market Overview

Recap: NeoGenomics Q1 Earnings



Shares of NeoGenomics (NASDAQ:NEO) decreased 0.1% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 100.00% year over year to ($0.04), which missed the estimate of $0.01.

Revenue of $115,533,000 rose by 8.96% from the same period last year, which beat the estimate of $112,410,000.


The upcoming fiscal year's EPS expected to be between ($0.27) and ($0.23).

The upcoming fiscal year's revenue expected to be between $490,000,000 and $510,000,000.

How To Listen To The Conference Call

Date: May 05, 2021

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $61.57

52-week low: $25.19

Price action over last quarter: down 2.50%

Company Overview

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.


Related Articles (NEO)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at